Skip to main content

Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.

Publication ,  Journal Article
Kaddurah-Daouk, R; Boyle, SH; Matson, W; Sharma, S; Matson, S; Zhu, H; Bogdanov, MB; Churchill, E; Krishnan, RR; Rush, AJ; Pickering, E ...
Published in: Transl Psychiatry
2011

The purpose of this study was to determine whether the baseline metabolic profile (that is, metabotype) of a patient with major depressive disorder (MDD) would define how an individual will respond to treatment. Outpatients with MDD were randomly assigned to sertraline (up to 150 mg per day) (N=43) or placebo (N=46) in a double-blind 4-week trial. Baseline serum samples were profiled using the liquid chromatography electrochemical array; the output was digitized to create a 'digital map' of the entire measurable response for a particular sample. Response was defined as ≥50% reduction baseline to week 4 in the 17-item Hamilton Rating Scale for Depression total score. Models were built using the one-out method for cross-validation. Multivariate analyses showed that metabolic profiles partially separated responders and non-responders to sertraline or to placebo. For the sertraline models, the overall correct classification rate was 81% whereas it was 72% for the placebo models. Several pathways were implicated in separation of responders and non-responders on sertraline and on placebo including phenylalanine, tryptophan, purine and tocopherol. Dihydroxyphenylacetic acid, tocopherols and serotonin were common metabolites in separating responders and non-responders to both drug and placebo. Pretreatment metabotypes may predict which depressed patients will respond to acute treatment (4 weeks) with sertraline or placebo. Some pathways were informative for both treatments whereas other pathways were unique in predicting response to either sertraline or placebo. Metabolomics may inform the biochemical basis for the early efficacy of sertraline.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Transl Psychiatry

DOI

EISSN

2158-3188

Publication Date

2011

Volume

1

Issue

7

Start / End Page

e26-

Location

United States

Related Subject Headings

  • Sertraline
  • Selective Serotonin Reuptake Inhibitors
  • Psychiatric Status Rating Scales
  • Outpatients
  • Middle Aged
  • Metabolomics
  • Metabolic Networks and Pathways
  • Male
  • Least-Squares Analysis
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kaddurah-Daouk, R., Boyle, S. H., Matson, W., Sharma, S., Matson, S., Zhu, H., … Delnomdedieu, M. (2011). Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry, 1(7), e26-. https://doi.org/10.1038/tp.2011.22
Kaddurah-Daouk, R., S. H. Boyle, W. Matson, S. Sharma, S. Matson, H. Zhu, M. B. Bogdanov, et al. “Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.Transl Psychiatry 1, no. 7 (2011): e26-. https://doi.org/10.1038/tp.2011.22.
Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, Zhu H, et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry. 2011;1(7):e26-.
Kaddurah-Daouk, R., et al. “Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.Transl Psychiatry, vol. 1, no. 7, 2011, pp. e26-. Pubmed, doi:10.1038/tp.2011.22.
Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, Zhu H, Bogdanov MB, Churchill E, Krishnan RR, Rush AJ, Pickering E, Delnomdedieu M. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry. 2011;1(7):e26-.

Published In

Transl Psychiatry

DOI

EISSN

2158-3188

Publication Date

2011

Volume

1

Issue

7

Start / End Page

e26-

Location

United States

Related Subject Headings

  • Sertraline
  • Selective Serotonin Reuptake Inhibitors
  • Psychiatric Status Rating Scales
  • Outpatients
  • Middle Aged
  • Metabolomics
  • Metabolic Networks and Pathways
  • Male
  • Least-Squares Analysis
  • Humans